JPMorgan Raises Price Target on Globe Life Inc. (GL) to $181 and Reiterates an Overweight Rating

Core Viewpoint - Globe Life Inc. is recognized as one of the 10 Most Profitable Undervalued Stocks to Buy, with a price target raised to $181 by JPMorgan analyst Jimmy Bhullar, reflecting a positive outlook on the company's earnings potential [1][6]. Financial Performance - For the fourth quarter, Globe Life Inc. reported revenue of $1.52 billion, slightly below the consensus estimate of $1.53 billion, indicating a minor shortfall in top-line performance [2]. - The company projects earnings for fiscal year 2026 to be between $14.95 and $15.65 per share, surpassing the consensus estimate of $15.03, suggesting management's confidence in continued earnings growth [2]. Business Overview - Globe Life Inc. specializes in providing life and supplemental health insurance products primarily targeting lower-middle- and middle-income households in the United States [3]. - The company operates through various subsidiaries, offering a diverse range of products including whole and term life policies, Medicare supplements, and limited-benefit health products such as accident, cancer, and critical illness coverage [3].